Inovio Pharma (INO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.12 +1.82%
EPS Growth %: +60.7%
Financial Fact:
Net loss/ (gain) attributable to non-controlling interest: 0
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: +60.7%
Financial Fact:
Net loss/ (gain) attributable to non-controlling interest: 0
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $1.74 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
- MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
- Yiren Digital Ltd. (YRD) Reports Q1 Loss of RMB5.64
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
